The Relationship between the Extent of Collaboration of General Practitioners and Pharmacists and the Implementation of Recommendations Arising from Medication Review A Systematic Review by Kwint, H.F. et al.
SYSTEMATIC REVIEW
The Relationship between the Extent of Collaboration of General
Practitioners and Pharmacists and the Implementation
of Recommendations Arising from Medication Review
A Systematic Review
Henk-Frans Kwint • Lynette Bermingham •
Adrianne Faber • Jacobijn Gussekloo •
Marcel L. Bouvy
 Springer International Publishing Switzerland 2013
Abstract
Background Many studies have investigated the effect of
medication review on a variety of outcomes, but the ele-
ments of the interventions have been quite diverse. More-
over, implementation rates of recommendations also vary
widely between studies.
Objective The objective of this study was to investigate
how the extent of collaboration between the general prac-
titioner (GP) and the pharmacist impacts on the imple-
mentation of recommendations arising from medication
review.
Methods MEDLINE, EMBASE and Web of Science
were searched for studies published between January 2000
and April 2012. Keywords included medication review,
medication therapy management, pharmaceutical services
and drug utilization review. Sixteen articles (describing 14
randomized controlled trials [RCTs]) out of 620 titles met
the inclusion criteria. Inclusion criteria for the review were
medication review, RCT design, involvement of both
pharmacist and GP, and home-dwelling patients (mean age
[70 years) who had not been recently discharged. After
quality assessment of the article, the presence of the fol-
lowing eight key elements reflecting collaboration were
scored for each intervention: pharmacist with clinical
experience, own pharmacist involved, sharing of medical
records, patient interview by pharmacist, invitation of
patients by GP, case conference between GP and pharma-
cist, action plan, follow-up. The primary outcome was the
implementation rate of recommendations. Meta-regression
analysis was used to assess the association between the
implementation rate and the number of key elements
present.
Results Twelve RCTs were included after quality
assessment. The mean number of key elements within the
intervention was 5.2 (range 1–8). The mean implementa-
tion rate of recommendations was 50 % (range 17–86). The
association between the number of key elements present in
the intervention and the implementation rate of recom-
mendations was significant: b = 0.085 (95 % CI
0.052–0.128; p \ 0.0001).
Conclusion This systematic review shows a significant
association between the number of key elements of the
intervention reflecting collaborative aspects in medication
review and the implementation rate of recommendations.
1 Introduction
Polypharmacy and drug-related morbidity is increasingly
recognized as a major public health problem among the
elderly [1, 2]. Medication review has been proposed as an
important strategy to constrain the negative effects of
polypharmacy, aiming at safer and more effective use of
medicines [3, 4].
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Medication review has been defined as ‘‘a structured,
critical examination of a patient’s medicines with the
objective of reaching an agreement with the patient about
treatment, optimising the impact of medicines, minimizing
the number of medication-related problems and reducing
waste’’ [5]. Three types of medication review have been
described, based on the purpose of the review: ‘prescription
review’ [technical issues related to prescription(s)], ‘con-
cordance or compliance review’ (issues relating to the
patient’s medicine behaviour) and ‘clinical medication
review’ (issues relating to the patient’s use of medicines in
the context of their condition) [6]. Concomitantly, efforts
have been made to standardize medication review [5–7].
However, systematic reviews of pharmacist-led medi-
cation review have not shown an effect on clinical out-
comes such as hospital admissions or mortality [8–10]. In
some studies, positive effects were reported on intermedi-
ate outcomes like drug knowledge and adherence [8]. The
heterogeneity in patient populations, settings, interventions
and outcomes in these studies made it difficult to draw
definitive conclusions. There may be merit in combining
the expertise of the pharmacist and physician with shared
decision-making involving the patient in order to improve
outcomes [11]. Previous systematic reviews did not take
into account the variability in collaboration between
pharmacists and general practitioners (GPs) in medication
reviews.
Studies on barriers and facilitators in medication review
reveal collaborative aspects that might be essential for
conducting successful medication reviews [12–14]. The
most commonly cited facilitators were having an estab-
lished pharmacist–physician relationship [13, 14] and a
face-to-face meeting (case conference) between pharmacist
and physician to discuss the pharmacist’s recommendations
[13, 15, 16]. Using a pharmacist other than the patient’s
regular pharmacist was seen as a barrier, as was inadequate
clinical training of the pharmacist [13]. Without access to
medical records, the pharmacist may make tentative or
inappropriate recommendations that are of little help [13].
The GPPC (General Practitioner–Pharmacist Collabora-
tion) study [17] further suggested that a general practice-
based service could be more facilitating than a community
pharmacy-based service [17]. This could imply that
patients are approached for medication review by the GP
practice, which is also common in the Home Medicines
Review (HMR) programme in Australia [12, 13]. They
further suggested that the pharmacist should meet the
patient for interview about their medicines in the physi-
cian’s office [17–19], while a patient interview at home by
an accredited pharmacist is the predominant step of the
HMR programme [12, 13]. Finally, it is important for a
collaborative medication review that responsibilities for
implementation of the action plan and follow-up are clearly
defined and divided between physician and pharmacist
[13].
The aim of this systematic review was to investigate
how the extent of collaboration between the GP and the
pharmacist impacts on the implementation of recommen-
dations arising from medication review.
2 Methods
2.1 Search
Our search strategy identified research on medication
review interventions involving pharmacists and GPs.
MEDLINE, EMBASE and Web of Science were searched
for articles published between 1 January 2000 and 1 April
2012. These dates were chosen because relatively few
studies with an elaborate description of the medication
review process were published before 2000. Interventions
were identified using the following keywords and medical
subject headings (MeSH): medication review, medication
therapy management, pharmaceutical services and drug
utilization review (see Appendix S1 for detailed search
terms [Online Resource 1]). Different publications on the
same group of patients were considered as one study.
2.2 Study Selection
All titles were reviewed by two investigators (H.K. and
L.B.). Studies were excluded if both agreed that the title
clearly indicated that the study did not concern medication
review and/or focussed on only one drug or drug class.
H.K. and L.B. assessed all remaining abstracts indepen-
dently in this manner. Studies were included if they
fulfilled the following criteria: medication review,
randomized clinical trial (RCT), pharmacist and GP
involved, home-dwelling patients in primary care, mean
age C70 years, patients not recently discharged
(\1 month).
Only studies in English were included. Finally, full
papers from potential studies were assessed independently
by the two investigators for their suitability for inclusion.
Differences were resolved by discussion, or a third inves-
tigator (either A.F. or M.B.) was consulted.
2.3 Quality Assessment of the Studies
Trial quality was assessed according to the Delphi list [20].
This list consists of ten criteria: randomization, treatment
allocation, similar groups at baseline, eligibility criteria,
blinding of outcome assessor, blinding of care provider,
blinding of patient, point estimates and measures of vari-
ability, intention-to-treat analysis and reporting of
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withdrawal/drop-out rate. In addition, we added ‘power
calculation’ to this list. Studies with a low score on the
quality assessment (5 or fewer items scored ‘yes’) were
excluded for analysis of outcomes.
2.4 Study Characteristics
2.4.1 Categorization
Studies were categorized by study author, year of publi-
cation, number of pharmacists and GPs, country, number of
patients, duration of the study, mean age and sex of
patients, mean number of drugs, description of the inter-
vention, setting, number of recommendations in the inter-
vention group, the clinical, intermediate and process
outcomes assessed and the quality score.
2.4.2 Outcomes
The primary outcome was the implementation rate of
recommendations following drug-related problems (DRPs)
identified during medication review. The implementation
rate was defined as the percentage of recommendations
fully or partly implemented and/or the percentage of DRPs
resolved. Partial implementation of recommendations
means that an action other than that originally proposed by
the pharmacist was implemented. Fully and partly imple-
mented recommendations were counted equally. Data on
clinical outcomes (hospital admissions, quality of life),
intermediate outcomes (adherence) and other process out-
comes (drug changes, number of drugs) were also extrac-
ted. The effect on clinical, intermediate and process
outcomes was described as a significant effect in favour of
the intervention group, a significant effect in favour of the
control group or no significant effect.
2.4.3 Key Elements of the Intervention
The intervention was characterized by the presence or
absence of eight key elements reflecting collaborative
aspects between a GP and a pharmacist, based on the
aforementioned facilitators and barriers in medication
review [12–14]. The choice of the key elements was sup-
ported by scientific discussion with experienced pharmacist
reviewers who regarded these elements as having ‘face
validity’. The following key elements were assessed: (1)
‘pharmacist with clinical experience’ means that the study
pharmacist had adequate clinical training and expertise to
perform medication reviews; (2) ‘own pharmacist
involved’ means that the study pharmacist is the patient’s
regular pharmacist who has a longer lasting therapeutic
relationship with his or her patient; (3) ‘sharing of medical
records’ describes full access for the care provider
performing the medication review to GP data on diseases
of the patient and clinical values; (4) ‘patient interview by
pharmacist’ means a face-to-face consultation between a
pharmacist and a patient—this pharmacist must have a
relationship with the GP; (5) ‘invitation of the patients by
GP’ means that the patient is invited to the study or referred
for medication review by the GP (practice); (6) ‘case
conference GP and pharmacist’ indicates a face-to-face
meeting between at least the GP and the pharmacist to
discuss the DRPs and recommendations for specific
patients; (7) ‘action plan’ means that the study investiga-
tors reported that the agreed recommendations were for-
mulated as an action plan and that there were designated
persons responsible for implementation of this plan; and
(8) ‘follow-up’ has taken place to assess whether the
actions have been implemented, and to assess the patient’s
experience with these actions.
2.5 Data Synthesis and Analysis
For each trial, we extracted data on the primary outcome,
‘implementation rate’. When the implementation rate was
not present, we derived this rate from the percentage of
DRPs resolved or the decrease in the number of potentially
inappropriate prescriptions (PIPs). Trial quality and key
elements of interventions were assessed independently by
the two investigators (H.K. and L.B.) for each included
study. Differences were resolved by discussion, or a third
investigator (either A.F. or M.B.) was consulted.
Meta-regression analysis was used to assess the associa-
tion between the number of key elements and the imple-
mentation rate, with the number of recommendations in the
different studies as possible effect moderator. This mixed-
effects analysis was conducted using the ‘metafor’ statistical
package in R (version 2.12.2, R Project for Statistical Com-
puting, Vienna, Austria, 2011, http://www.R-project.org).
3 Results
3.1 Search Results
A total of 620 titles were identified, 16 of which
(describing 14 RCTs) met the inclusion criteria and were
included in this review (Fig. 1) [3, 15–17, 19, 21–32].
3.2 Quality Assessment of Studies
The methodological quality of 12 of the 14 studies was
assessed as adequate (i.e. 6 or more of 11 items scored
‘yes’) 3, 15–17, 19, 21, 23–27, 29–32] (see Table S1 in
Appendix S2 [Online Resource 1]). The quality of the trial
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in the two remaining studies was scored as ‘low’ [22, 28]
and they were therefore excluded from further analysis.
These studies were related; one trial formed part of a larger
co-ordinated project with more countries, which was
described in the other paper [22, 28].
In all included studies, a method of randomization was
performed and eligibility criteria were specified. The
majority of studies reported a method of treatment allo-
cation [3, 15–17, 22–26, 29–31], while in three studies this
was either not clearly described or not conducted [19, 21,
27, 32]. All except two studies reported similar groups at
baseline [28–30]. An independent outcome assessor who
was blinded to the intervention allocation was clearly
described in only two studies [17, 21]. Because of the
nature of the studied intervention, the care provider was
never blinded to the intervention allocation. The patient
was blinded for the intervention allocation in three studies
[3, 15, 16, 23]. In two of these studies, patient interviews
were conducted for both the intervention and the control
group, but a pharmaceutical care plan was implemented
only for the intervention group [3, 23]. In the third study,
no patient interview was conducted and there was no
description of patient involvement with the study [15, 16].
Point estimates and measures of variability were described
in all studies. Intention-to-treat analysis was conducted in
five studies [19, 21, 23, 25, 27, 32]. The withdrawal rate
was likely to have caused bias in 3 of 14 studies [3, 15, 16,
19, 21, 23–27, 29–32].
3.3 Study Characteristics
In Table 1, the study characteristics and outcomes are
presented for the 12 included studies. The number of par-
ticipants in these studies ranged from 118 to 1,188. The
mean age of the participants was 76.6 years (range
71.8–84.3) and 66 % were females (range 56–90). The
mean number of prescribed drugs was 7.2 (range 4.5–12).
Three of these studies were performed in the US [23, 29–
31], three in the UK [3, 19, 25, 32] and two in The
Netherlands [15, 16, 24].
3.3.1 Outcomes
Seven of 12 studies provided data on clinical outcomes
[3, 17, 19, 25–27, 29, 32]. Six of these studies reported
on quality of life measured using the 36-item Short Form
Health Survey (SF-36) [3, 17, 19, 26, 27, 29, 32] or the
EuroQoL-5D/visual analogue scale (VAS) [25]. No
effects were found on total scores for quality of life, and
one study reported only negative effects on some
domains in one study [17]. Data on hospital admissions
were provided by four studies [19, 25–27, 32], and no
significant effects were reported. Twelve studies provided
data on intermediate outcomes. Two studies reported on
adherence, either self-reported [29, 30] or measured by
refill rate [23], with no effect. Two studies reported on
DRPs in both the intervention and the control group,
with positive effects on DRPs resolved [3, 24]. Two
studies [17, 21] reported on potentially inappropriate
medications (PIMs), with positive effects for one study
[17]. Process outcomes were reported in all studies. Two
studies reported a reduction in the number of (pre-
scribed) drugs [19, 31, 32], while in four studies no
effect was reported [21, 23, 25, 26]. Five studies
reported an increase in the number of drug changes [15–
17, 19, 24, 31, 32].
Implementation rates of recommendations in the inter-
vention group are shown in Table 2. The percentage of
implemented recommendations was reported in seven
studies [15–17, 19, 23, 25–27, 32], while a percentage of
resolved DRPs was mentioned in three studies [3, 24, 29,
30]. In two studies, the implementation rate was derived
from the decrease in the number of PIPs compared with the
total number of PIPs [21, 31].
Potentially relevant publications
identified and titles screened
(n = 620)
Excluded because:: 
• no RCT (n = 95)
• secondary or tertiary care (n = 20)
• targeting specific disease (n = 8)
• discharge (n = 7)
• age too low (n = 1)







Publications included in review
(n = 16)
describing 14 RCTs
Excluded on basis of title alone 
because intervention is not 
medication review, and/or targeting 
specific drugs (n = 467) 
Excluded because:
• age too low (n = 3)
• targeting specific drug classes (n = 2)
• medication review only part of 
intervention (n = 1)
Fig. 1 Flow chart describing study selection and excluded studies.
RCT randomized, controlled trial
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3.3.2 Key Elements of the Intervention
Key elements of 13 interventions from the 12 studies are
shown in Table 2. One study compared outcomes between
two intervention groups (case conference and written
feedback [15, 16]), and therefore both study arms (A and
B) are shown.
Pharmacists had clinical experience in 10 of the 13
interventions [3, 17, 19, 23, 25–27, 29–31]. Pharmacists
were accredited pharmacists [17, 27], consultant pharma-
cists [23, 31] or clinical pharmacists [19, 32]. They fol-
lowed a university accredited externship programme [26],
were clinically trained [3], experienced in medication
reviews [24, 25] or had a post-graduate qualification in
pharmacy practice [25]. In 8 of 13 interventions, the
patient’s own GP was involved [15–17, 25–27, 29, 30]. In
the other interventions, the study pharmacist had no
existing therapeutic relationship with the patient or this was
not described [3, 19, 21, 23, 31, 32] (see also Table 1).
Pharmacists had full access to GP’s medical records of the
patient in 8 of the 13 interventions [3, 17, 19, 25–27, 29,
32]. Patient interviews were conducted in 11 of 13 inter-
ventions, at home [3, 17, 21, 23, 25, 27] or in the GP’s
office or clinic [19, 26, 31, 32]. In 3 of 13 interventions,
eligible patients were invited by the GP to participate in the
study [17, 19, 27, 32]. Case conferences between GPs and
pharmacists were conducted in 7 of 13 interventions [15–
17, 19, 24–27, 32]. In three interventions, letters with
recommendations or care plans were sent to the GPs
(‘written feedback’) [3, 15, 16, 23]. As mentioned earlier,
one study compared the process outcomes of case confer-
ences with written feedback [15, 16]. As part of two
interventions, case conferences were held by external
multidisciplinary teams without the patient’s own GP [21,
31] and recommendations were mailed to the GP [21] or
implemented with endorsement of the GP [31]. Action
plans were used for implementation of agreed
recommendations in 9 of 13 interventions [3, 15–17, 19,
24–27, 29, 32]. A follow-up of the implementation of
actions was described in 11 of 13 interventions [3, 15–17,
19, 21, 23, 25–27, 29, 31, 32], most often conducted by a
pharmacist [15, 17, 19, 23, 25, 26, 31, 32].
3.4 Association between Number of Key Elements
and Outcomes
Key elements of the intervention and the implementation
rate are shown in Table 2. The mean number of key ele-
ments present in the interventions was 5.2 (range 1–8). The
mean implementation rate was 50 % (range 17–86).
The association between the number of key elements
present in the intervention and the implementation rate of
recommendations was positive: an increase in number of
key elements was related to an increase in implementation
rate, b = 0.085 (95 % CI 0.052–0.128; p \ 0.0001)
(Fig. 2). Figure 3 is a forest plot showing the observed and
expected implementation rates, estimated on the meta-
analysis association between number of key elements and
the implementation rate. In all but three interventions, the
observed implementation rate was within the 95 % confi-
dence interval of the expected value [3, 19, 27, 32].
No meta-regression analyses were possible for the
association between the number of key elements and the
number of hospital admissions (n = 4 studies), the number
of drug changes (n = 5 studies) and the number of pre-
scribed drugs (n = 5 studies), because of the low number
of studies and participants with these outcomes.
4 Discussion
This systematic review shows a significant association
between the number of key elements of the intervention
reflecting collaborative aspects in medication review and
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Fig. 2 Bubble plot of number
of key elements of intervention
vs. implementation rate of
recommendations. The size of
the circles reflects the number of
recommendations in the
intervention group of the
different studies [3, 15, 17, 21,
23–27, 29, 31, 32]
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the implementation rate. This suggests that more intensive
collaboration between GP and pharmacist in medication
review leads to higher recommendation implementation
rates.
The expected implementation rate could be predicted
from the number of key elements estimated from this asso-
ciation (Fig. 3). This model gives a good prediction of the
implementation rate for the majority of the studies. For three
studies, the expected implementation rate was different from
the observed value [3, 19, 27, 32]. A higher implementation
rate than expected was observed in the studies by Krska et al.
[3] and Zermansky et al. [19, 32]. In the study by Zermansky
et al. [19, 32], one pharmacist collaborated with only a few
GPs, similar to the study by Lenaghan et al. [25], resulting in
comparably high implementation rates. The major differ-
ence with the Lenaghan study was that the patient’s own
pharmacist was not involved. However, it is conceivable that
this (clinical) pharmacist established a good relationship
with this small number of GPs and their patients whilst he
was consulting patients in the GP’s office. Studies with
pharmacists working at a GP practice yielded high rates of
acceptance of recommendations [18, 19, 26, 32]. Con-
versely, Krska et al. [3] was the only study with a high
implementation rate without a case conference. This face-to-
face meeting between GPs and pharmacists to discuss the
pharmacist’s recommendations is often considered one of
the most important and key elements of the collaborative
approach in medication review [13, 15, 16, 33]. In the study
by Krska et al. [3], pharmacists were assisted by practice staff
in the implementation of accepted actions. Possibly, this
partly explains the high implementation rate. Furthermore,
the nature and number of pharmacists and their relationship
with patients was not specified [3]. On the other hand, a lower
than expected implementation rate was observed in the
intervention by Sorensen et al. [27]. In this study, a large
number of pharmacists collaborated with an even larger
number of GPs, which could have made it difficult to achieve
high implementation rates. The implementation rate and
numbers of GPs and pharmacists in the study of Sorensen
et al. [27] were similar to those in the study by Sellors et al.
[26]. The major difference was that, in the study of Sorensen
et al. [27], patients were invited by the GP.
There have been no earlier systematic reviews investi-
gating the implementation rate of recommendations. We
found a significant association between the number of key
elements reflecting collaborative aspects and the imple-
mentation rate. This finding is in agreement with other
medication review studies in secondary and tertiary care
where direct communication between healthcare providers
revealed higher acceptance rates of recommendations [34,
35]. For clinical and intermediate outcomes, no association
could be assessed, because the number of studies reporting
these outcomes was too low. Earlier systematic reviews
reported no effect on hospital admissions and quality of life
[8, 10]. Compared with these reviews, our scope was more
focused, as we included only RCTs, home-dwelling
patients in primary care, a mean age of 70 years and no
recent discharge, yielding only 12 trials after quality
0 25 50 75 100
Implementation rate (%)
Zermansky et al. (2001)
Lenaghan et al. (2007)
Krska et al. (2001)
Bryant et al. (2011)
Volume et al. (2001)
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Sorensen et al. (2004)
Williams et al. (2004)
Denneboom et al.
study arm A (2007)
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Allard et al. (2001)
Denneboom et al.














Mean [CI]Study (year of publication)Fig. 3 Forest plot of observed
and expected implementation
rate of recommendations [3, 15,
17, 21, 23–27, 29, 31, 32]. Mean
observed implementation rate
with confidence intervals (95 %
CIs). The grey diamonds
represent the CIs of the
expected implementation rate
estimated on the meta-
regression analysis association
between the number of key
elements and the
implementation rate
GP/Pharmacist Collaboration in Medication Review
assessment. However, due to our inclusion criteria, patients
in our review were relatively healthy and not directly at
risk for hospital admission. In contrast, studies on medi-
cation review in hospitals were more successful in pre-
venting hospital (re)admissions because they generally
reviewed patients who were admitted to hospital and at
high risk for readmission [36, 37].
There may be additional reasons for low implementation
rates. Sellors et al. [26] showed that these reasons might
include patient reluctance, previous failed attempts at the
same strategy and a relatively short period for implemen-
tation combined with the occurrence of more urgent issues.
In particular, the periods over which implementation rates
were measured varied between the different studies in this
review. Nor do we know if the recommendations in the
different studies were clinically appropriate [17]. GP’s
perceptions of pharmacists’ recommendations in the GPPC
study revealed that they generally found the recommen-
dations useful although at times theoretical [38]. Pharma-
cist’s recommendations may be less appropriate if a high
proportion of patients are already receiving the recom-
mended treatment, for example, in the MEDMAN study
(‘ceiling effect’) [39].
There were several strengths to this study. First of all,
like in other systematic reviews on medication review,
trials reported very heterogeneous outcomes that could not
be pooled. In this systematic review, we could compare
different trials using the implementation rate as the com-
mon (process) outcome. Implementation rates are also
reported in many (observational) studies in home-dwelling
patients [40, 41] as well as for patients in nursing homes
[34, 42]. Implementation rate has a greater significance
than acceptance rate of pharmacist’s recommendations by
physicians because it includes enactment of the recom-
mendation by a care provider and the level of acceptance of
recommendations by the patient. Secondly, we described
eight different elements of the intervention that reflect
collaborative aspects between GPs and pharmacists. These
key elements were based on described facilitators and
barriers in medication review [12–14]. Thirdly, the
importance of patient involvement in medication review
was also reflected by the key elements ‘own pharmacist
involved’, ‘patient interview’ and ‘follow-up’.
Our decision to consider all eight key elements of the
intervention as equivalent weighted determinants for the
implementation rate could be seen as a limitation. For
example, the face-to-face discussion between pharmacists
and GPs seemed a key element that could have more
weight. The small number of studies precluded us from
studying the association of the individual key elements in a
multivariate design. Also, there could have been other key
elements reflecting collaborative aspects that we may have
missed. Furthermore, it was not possible to discriminate
between the clinical relevance of the implemented rec-
ommendations in the different studies. This clinical rele-
vance was only described in the study by Denneboom et al.
[15, 16]. Finally, it cannot be ruled out that some relevant
RCTs may have been missed or excluded.
5 Conclusion
This systematic review showed that the number of key
elements reflecting collaborative aspects of medication
review was significantly associated with the recommen-
dation implementation rate. Further clinical trials could
demonstrate whether an increase in collaborative aspects
leads to higher implementation rates.
Based on this model, future studies for elderly in pri-
mary care could consider these key elements of interven-
tion to design a standardized medication review process.
More research is needed to assess which key elements of
this collaborative approach are the most important and if
there are additional elements that may influence imple-
mentation rates. Next to the physician and the pharmacist,
the patient is the third main player in the medication review
process. Future studies could focus on the influence of the
patient on the implementation rate. Large multicentre trials
in primary care are needed to draw definitive conclusions
on whether a standardized collaborative approach in med-
ication review could affect clinical outcomes. Such trials
may be expensive, difficult to organize in practice settings
and it may be questioned how many and which elderly
home-dwelling patients in primary care are at greatest risk
for negative clinical outcomes.
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